Article Versions Notes

Han HS, Kim W-S, Lee Y, Won C-H, Lee W, Choi SY, Kim BJ. Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19. Toxins. 2025; 17(4):160. https://doi.org/10.3390/toxins17040160

Han, Hye Sung, Won-Serk Kim, Yangwon Lee, Chong-Hyun Won, Wooshun Lee, Sun Young Choi, and Beom Joon Kim. 2025. "Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19" Toxins 17, no. 4: 160. https://doi.org/10.3390/toxins17040160

Han, H. S., Kim, W.-S., Lee, Y., Won, C.-H., Lee, W., Choi, S. Y., & Kim, B. J. (2025). Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19. Toxins, 17(4), 160. https://doi.org/10.3390/toxins17040160